Agios Pharmaceuticals, Inc.
AGIO
$25.86
-$1.85-6.68%
| Weiss Ratings | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C- | |||
| Rating Factors | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.23 | |||
| Price History | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.93% | |||
| 30-Day Total Return | -26.58% | |||
| 60-Day Total Return | -26.37% | |||
| 90-Day Total Return | -53.44% | |||
| Year to Date Total Return | -18.78% | |||
| 1-Year Total Return | -7.38% | |||
| 2-Year Total Return | 19.72% | |||
| 3-Year Total Return | -17.70% | |||
| 5-Year Total Return | -34.53% | |||
| 52-Week High % Change | -55.72% | |||
| 52-Week Low % Change | 3.96% | |||
| Price | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $62.58 | |||
| 52-Week Low Price | $26.66 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.59B | |||
| Enterprise Value | 112.63M | |||
| Price/Earnings (TTM) | 2.43 | |||
| Earnings Per Share (TTM) | 11.39 | |||
| Earnings Per Share Growth | -279.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 43.36 | |||
| Price/Book (Q) | 1.03 | |||
| Enterprise Value/Revenue (TTM) | 3.09 | |||
| Price | $25.86 | |||
| Enterprise Value/EBITDA (TTM) | -0.27 | |||
| Enterprise Value/EBIT | -0.26 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 57.10M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 649 8600 | |||
| Address | 88 Sidney Street Cambridge, MA 02139 | |||
| Website | www.agios.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,166.46% | |||
| Profit Margin | 1,845.92% | |||
| Management Effectiveness | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -20.47% | |||
| Return on Equity | 57.29% | |||
| Income Statement | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 36.50M | |||
| Total Revenue (TTM) | 36.50M | |||
| Revenue Per Share | $0.64 | |||
| Gross Profit (TTM) | -268.95M | |||
| EBITDA (TTM) | -420.08M | |||
| EBIT (TTM) | -425.74M | |||
| Net Income (TTM) | 673.73M | |||
| Net Income Avl. to Common (TTM) | 673.73M | |||
| Total Revenue Growth (Q YOY) | 51.06% | |||
| Earnings Growth (Q YOY) | -0.61% | |||
| EPS Diluted (TTM) | 11.39 | |||
| EPS Diluted Growth (Q YOY) | 1.67% | |||
| Balance Sheet | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 893.71M | |||
| Cash Per Share (Q) | $15.65 | |||
| Total Current Assets (Q) | 965.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.54B | |||
| Current Ratio (Q) | 11.898 | |||
| Book Value Per Share (Q) | $26.96 | |||
| Total Assets (Q) | 1.66B | |||
| Total Current Liabilities (Q) | 81.16M | |||
| Total Debt (Q) | 56.99M | |||
| Total Liabilities (Q) | 122.24M | |||
| Total Common Equity (Q) | 1.54B | |||
| Cash Flow | AGIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 363.44M | |||
| Cash from Financing (TTM) | 14.44M | |||
| Net Change in Cash (TTM) | -11.96M | |||
| Levered Free Cash Flow (TTM) | -222.83M | |||
| Cash from Operations (TTM) | -389.84M | |||
